Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
72.00    2.00 (2.86%)
Bid:
71.00
Ask:
73.00
Spread: 2.00 (2.817%)
Market Cap: £327.68m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Additional Listing

18 Feb 2013 17:08

RNS Number : 1422Y
Avacta Group PLC
18 February 2013
 

 

 

18 February 2013

 

 

Avacta Group plc

 

Issues of Equity

 

Avacta Group plc (the "Company") announces that 500,000 ordinary shares of 0.1p each ("Ordinary Shares") have been issued at a price of 0.25p per share, pursuant to the exercise of share warrants. The warrants were granted during May 2006, prior to the reversal of Avacta Limited into the Company, then named Readybuy plc.

Application has been made for the 500,000 Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 22 February 2013.

 

The total number of Ordinary Shares, with voting rights, in issue following the above two issues of shares will be 3,157,344,912.

 

 

Enquiries:

 

Avacta Group plc

Tel: 0844 414 0452

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

www.avacta.com

Stockbroker and Nominated Adviser

Panmure Gordon (UK) Limited

Charles Leigh-Pemberton/Fred Walsh

Tel: 020 7459 3600

www.panmure.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISLLFERFAITLIV
Date   Source Headline
11th Nov 20197:00 amRNSHolding(s) in Company
8th Nov 20196:30 pmRNSHolding(s) in Company
8th Nov 20196:26 pmRNSHolding(s) in Company
7th Nov 20191:00 pmRNSHolding(s) in Company
7th Nov 201911:00 amRNSHolding(s) in Company
6th Nov 20192:30 pmRNSHolding(s) in Company
4th Nov 20191:18 pmRNSResult of General Meeting
18th Oct 201912:06 pmRNSProposed Placing & Subscription to raise up to £9M
18th Oct 201912:05 pmRNSInterim Results for the Period Ended 31 July 2019
10th Oct 20197:00 amRNSCollaboration with ADC Therapeutics
5th Aug 20199:05 amRNSSecond Price Monitoring Extn
5th Aug 20199:00 amRNSPrice Monitoring Extension
29th Jul 20197:00 amRNSAvacta's CEO to Present at Biotech Investor Day
20th Jun 20197:00 amRNSAvacta and Selexis Partner to Develop Cell Line
19th Jun 20197:00 amRNSTurner Pope Investor Evening
12th Jun 20197:00 amRNSAvacta's CSO to Present at Major US Conference
10th Jun 20197:00 amRNSAvacta hits Clinical Candidate Selection Milestone
3rd Jun 20197:00 amRNSTMAC Programme Accelerates
23rd Apr 20193:48 pmRNSIssue of Equity
12th Apr 20192:46 pmRNSHolding(s) in Company
9th Apr 20197:00 amRNSInterim Results
8th Mar 201912:14 pmRNSIssue of Equity
6th Feb 201912:27 pmEQSHardman & Co Research: Avacta (AVCT): A second wake-up call for the market
4th Feb 20197:00 amRNSModerna Exercises Exclusive Product License Option
28th Jan 20197:00 amRNSDirector Appointment
21st Jan 20193:40 pmRNSResult of Annual General Meeting
21st Jan 20197:00 amRNSAGM Business Update and Notice of Results
18th Jan 20195:08 pmRNSShare Incentive Plan/Issue of Equity
9th Jan 201911:06 amRNSHolding(s) in Company
7th Jan 20192:50 pmRNSDirector/PDMR Shareholdings
3rd Jan 20198:56 amRNSHolding(s) in Company
2nd Jan 20197:00 amRNSDirector/PDMR Shareholding
21st Dec 20181:41 pmRNSHolding(s) in Company
19th Dec 20183:32 pmRNSHolding(s) in Company
17th Dec 20187:00 amRNSAvacta London Science Day
12th Dec 201812:50 pmRNSHolding(s) in Company
12th Dec 201812:44 pmRNSHolding(s) in Company
12th Dec 20187:00 amRNSAppointment of Chief Medical Officer
11th Dec 20187:00 amRNSPosting of Annual Report and Notice of AGM
10th Dec 20182:05 pmRNSSecond Price Monitoring Extn
10th Dec 20182:00 pmRNSPrice Monitoring Extension
10th Dec 20187:30 amEQSHardman & Co Research: Avacta (AVCT): Wake-up call for the market
10th Dec 20187:00 amRNSDevelopment Partnership with LG Chem Life Sciences
12th Nov 20187:00 amRNSAvacta to Present at Major European Conference
11th Oct 20187:00 amRNSAvacta's CTO to Present at Major US Conference
10th Oct 20187:00 amRNSAvacta agrees Affimer reagent licensing deal
2nd Oct 20187:00 amRNSPreliminary Results
21st Sep 20187:00 amRNSInvestor Meeting and Presentation
5th Sep 20187:15 amEQSHardman & Co Research: Avacta (AVCT): Capital increase for further development
5th Sep 20187:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.